This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Skorpen, F Articles by Kaasa, S Search for Related Content PubMed PubMed Citation Articles by Skorpen, F Articles by Kaasa, S Social Bookmarking                   What's this?

Variable response to opioid treatment: any genetic predictors within sight?

Department of Laboratory Medicine, Children’s and Women’s Health, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, frank.skorpen{at}ntnu.no

EA Laugsand

Department of Laboratory Medicine, Children’s and Women’s Health, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim

P Klepstad

Department of Circulation and Medical Imaging, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim; Department of Intensive Care, St Olavs University Hospital, Trondheim

S Kaasa

Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim; Department of Palliative Care, St Olavs University Hospital, Trondheim

The aim of this literature review is to summarize and discuss the available evidence for a relationship between polymorphisms in human genes and variability in opioid analgesia and side effects among patients treated for moderate or severe pain. The evidence supporting a role of certain alleles, genotypes or haplotypes in modulation of opioid analgesia is derived from a limited number of studies, a limited number of genes and a limited number of opioids. Although several interesting candidates have emerged as potentially relevant factors, only for one polymorphism, the prevalent 118A>G of the µ-opioid receptor, the accumulated evidence is sufficient to suggest a clinically relevant effect for an opioid used for moderate or severe pain. Still the data are valid only at the group level and cannot be used to predict treatment outcome in individual patients. Only a few of the symptoms often seen as opioid adverse effects in palliative care, such as nausea, vomiting, constipation and sedation, have been associated with genetic variants in various genes, but the results have been based on case reports, healthy volunteers or post-operative patients. So far, there is no clear evidence that genetic markers can be used to predict opioid efficacy or adverse effects in palliative care patients. This reflects the general lack of studies performed in the context of palliative care, the lack of sufficiently scaled studies and the lack of international standards for the assessment of subjective symptoms.

Key Words: adverse effects • analgesia • analgesics • opioid • palliative care • pharmacogenetics

Palliative Medicine, Vol. 22, No. 4, 310-327 (2008)
DOI: 10.1177/0269216308089302


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. A. Adegbola Can Heterogeneity of Chronic Sickle-Cell Disease Pain Be Explained by Genomics? A Literature Review Biol Res Nurs, July 1, 2009; 11(1): 81 - 97. [Abstract] [PDF]

				J R Ross and J Riley Commentary: Controversies in SIGN guidance on pain control in patients with cancer BMJ, November 5, 2008; 337(nov05_1): a2234 - a2234. [Full Text]

				S Kaasa Editorial: Palliative care research - time to intensify international collaboration Palliative Medicine, June 1, 2008; 22(4): 301 - 302. [PDF]